Aleix Prat
Hospital Clinic · Hospital Clínic de Barcelona/SOLTI · Hospital Clínic of Barcelona / SOLTI
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aleix Prat as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05451784 · Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILSFundacio Clinic Barcelona · recruiting · Metastatic Triple-Negative Breast Carcinoma · study chair
- Ph2NCT05296746 · Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerSOLTI Breast Cancer Research Group · active not recruiting · Breast Cancer Stage II · principal investigator
- Ph3NCT05207709 · Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeSOLTI Breast Cancer Research Group · terminated · Metastatic Breast Cancer · principal investigator
- Ph2NCT04578106 · Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant TherapyFundacio Clinic Barcelona · terminated · HER2-positive Breast Cancer, Stage I Breast Cancer · principal investigator
- Ph2NCT04251169 · Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor ProgressionSOLTI Breast Cancer Research Group · terminated · Metastatic Breast Cancer · principal investigator
- Early Ph1NCT03802604 · Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerSOLTI Breast Cancer Research Group · completed · Breast Cancer · principal investigator
- Ph2NCT03248427 · Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.SOLTI Breast Cancer Research Group · completed · Breast Cancer · principal investigator
- Early Ph1NCT02802748 · Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)SOLTI Breast Cancer Research Group · completed · Breast Cancer · principal investigator
- Ph2NCT01973660 · PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerSOLTI Breast Cancer Research Group · completed · Breast Cancer · study chair
- Ph2NCT01669252 · Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast CancerSOLTI Breast Cancer Research Group · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:47 UTC. The ranking covers the 200 most relevant of 83 PubMed records, and a shared surname and initials can bring in a namesake. All 83 on PubMed
- 2,392 citationsRCR 180.8
- 435 citationsRCR 10.1
- 284 citationsRCR 8.2
- 281 citationsRCR 13.6
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.Lancet Oncol · 2021218 citationsRCR 10.7
- 176 citationsRCR 6.4
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.Lancet Oncol · 2023152 citationsRCR 12.3
- 140 citationsRCR 6.8
- 124 citationsRCR 3.3
- Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.J Clin Oncol · 2021122 citationsRCR 5.7